Areas of Expertise:
Investigational new drugs for childhood cancer
Locations: Main Campus
Areas of Expertise:
Investigational new drugs for childhood cancer
Locations: Main Campus
Creating disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside.
As the chair of the Children's Oncology Group (COG), a group of more than 200 leading children’s hospitals, universities, and cancer centers that brings together more than 9,000 international experts in childhood cancer, I am in frequent contact with leading researchers around the world.
There are a wide range of opportunities focusing on improving the outcome for children with cancer, and we are hard at work trying to speed the timeline so the most promising new therapies can move forward. We are working on creating better pathways for disease-targeted therapies for children with cancer, and are focusing our efforts on transforming how new discoveries can move from the bench to the bedside, a process called translational research. At any given time, the Children’s Oncology Group oversees more than 60 active phase I, phase II and phase III pediatric and adolescent cancer clinical trials that enroll approximately 9,000 patients annually.
Before becoming chair of the COG, I led a group of 21 institutions that performed the initial evaluation of new drugs for children with cancer. During the more than eight years that I led the COG Phase 1 Consortium, we conducted numerous phase I studies. These studies are the first clinical trials of new anticancer drugs in children whose cancer has recurred despite best-known treatments. I thus have direct knowledge of the investigational new drug trials being conducted not only at Children's Hospital, but at centers worldwide. This allows me to serve as a resource on experimental cancer treatment for Children's Hospital clinicians. For the child whose cancer has recurred, these are the kinds of trials they often seek out.
We have come a long way in our ability to cure children with many types of cancer, but we must continue working to find cures for all children. We also must develop treatments that have fewer side effects. Together with the COG, doctors at Children's Hospital are helping to lead the way in this effort.
MD - Cornell University Medical College, New York, NY
Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology/Oncology - National Cancer Institute, Washington, DC
Clinical PharmacologyPediatric Hematology-OncologyPediatrics
Chair, Children’s Oncology Group
Alan R. Cohen Endowed Chair in Pediatrics
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015. doi: 10.1002/pbc.25454. PubMed PMID: 25732247.
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015. doi: 10.1002/pbc.25569. PubMed PMID: 25946708.
G Salazar E, Bernhardt MB, Li Y, Aplenc R, Adamson PC. The impact of chemotherapy shortages on COG and local clinical trials: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015. doi: 10.1002/pbc.25445. PubMed PMID: 25704486.
Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015;62(1):45-51. doi: 10.1002/pbc.25229. PubMed PMID: 25257751; PMCID: 4237627.
Moorthy GS, Norris RE, Adamson PC, Fox E. A liquid chromatography/tandem mass spectrometry method for determination of obatoclax in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;971:30-4. doi: 10.1016/j.jchromb.2014.09.005. PubMed PMID: 25261914; PMCID: 4252240.
Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. PubMed PMID: 25348002; PMCID: 4239306.
Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, Stork SK, Adamson PC, Ross JA. The Children's Oncology Group Childhood Cancer Research Network (CCRN): Case Catchment in the United States. Cancer. 2014. doi: 10.1002/cncr.28813. PMID: 24889136.
Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014;61(3):452-6. doi: 10.1002/pbc.24605. PMID: 23956055.
Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer. 2014. doi: 10.1002/cncr.28748. PMID: 24853691.
Norris RE, Nguyen VT, Adamson PC. Evaluation of the retinoids with cisplatin and vincristine in xenograft models of neuroblastoma. J Pediatr Hematol Oncol. 2014;36(1):e23-7. doi: 10.1097/MPH.0b013e3182915d4a. PMID: 23669732; PMCID: PMC3766379.
Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer. 2014;61(1):145-50. doi: 10.1002/pbc.24697. PMID: 24038812; PMCID: PMC3849815.
Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton P, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Janeway KA, Weigel BJ, Randall RL, Meltzer PS, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Uren A, Patel S, Trent JM, Savage SA, Mirabello L, Reinke D, Barkauskas DA, Smith MA, Bernstein ML, Kirsch DG, Krailo MD. Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma. Clin Cancer Res. 2014. doi: 10.1158/1078-0432.CCR-13-2574. PMID: 24803583.
Fox E, Mosse YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014;61(6):990-6. doi: 10.1002/pbc.24900. PMID: 24347462.
Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer. 2014;61(5):833-9. doi: 10.1002/pbc.24874. PMID: 24249672.
Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 2013 Feb;60(2):237-41. PMID: 22745043. PMCID: 3463652.
Dlugos D, Shinnar S, Cnaan A, Hu F, Moshe S, Mizrahi E, Masur D, Sogawa Y, Le Pichon JB, Levine C, Hirtz D, Clark P, Adamson PC, Glauser T, Childhood Absence Epilepsy Study T. Pretreatment EEG in childhood absence epilepsy: associations with attention and treatment outcome. Neurology. 2013 Jul 9;81(2):150-6. PMID: 23719147. PMCID: 3770172.
Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The Lancet Oncology. 2013;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. PMID: 23598171.
Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer. 2013;60(2):237-41. doi: 10.1002/pbc.24244. PMID: 22745043
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC, for the Childhood Absence Epilepsy Study T. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141-55. doi: 10.1111/epi.12028. PMID: 23167925
Widemann BC, Adamson PC. Fundamentals of Cancer Chemotherapy. In: Carroll WL, Finlay JL, editors. Cancer in Children and Adolescents. Boston: Jones and Bartlett; 2010. p. 95-112.
Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC. Recommended changes to oncology clinical trial design: Revolution or evolution? Eur J Cancer. 2008 Jan;44(1):8-11.
The American Society of Pediatric Hematology/ Oncology (ASPHO) 2015 Meeting, “Future State of Clinical Trial Design”, Phoenix, AZ, May 6-8, 2015.
Twenty First Annual Blood-Brain Barrier Consortium Meeting, “Clinical Trial Challenges: Development of Chemoprotectants for Children with Cancer”, Stevenson, WA, March 19-20, 2015.
Grand Rounds – Texas Children’s Hospital, “Development of Targeted New Agents for Children with Cancer”, Houston, TX, March 13, 2015.
Grand Rounds – MD Anderson Cancer Center, “Development of Targeted New Agents for Children with Cancer”, Houston, TX, March 2, 2015.
Grand Rounds – Vanderbilt Children’s Hospital, “Developing Targeted New Agents for Children with Cancer”, Nashville, TN, February 10, 2015.
CDDF 3rd Paediatric Oncology Conference, “The US Strategy for Paediatric Oncology Drug Development”, Vienna, Austria, February 5-6, 2015.
King Faisal Specialist Hospital & Research Centre-Jeddah, “Advances in the Treatment of Childhood Hematologic Malignancies”, “Development of Targeted New Agents for Children with Cancer”, “Leads from Childhood Cancer Research”, Jeddah, Saudi Arabia, November 3-5, 2014.
International Society of Paediatric Oncology (SIOP) Annual Meeting, “US Funding for Childhood Cancer Research”, Toronto, CA, October 24, 2014.
Society for Adolescent and Young Adult Oncology, “A Strategic Approach to Discovery & Clinical Trials in the Emerging Era of Targeted Therapy”, Irvine, CA, October 7, 2014.
EFGCP/DIA/ EMA Annual Conference 2014 on Better Medicines for Children, “Enhanced Global Collaboration”, London, England, October 1, 2014.
NIGMS-NICHD Pediatric Clinical Pharmacology, “Role of Clinical Pharmacology in Pediatric Cancer Drug Development”, Bethesda, MD, August 25, 2014.
Memorial Sloan Kettering Cancer Center, “Development of Targeted New Agents for Children with Cancer”, New York, NY, May 8, 2014.
National Coalition for Cancer Survivorship Meeting, “Getting New Medicines to Patients Faster: Innovative Approaches”, Washington, DC, April 29, 2014.
Biotechnology Industry Organization (BIO) Pediatrics Stakeholders Meeting, “Addressing Challenges to Clinical Development of Pediatric Drug”, Washington DC, April 25, 2014.
Case Comprehensive Cancer Center, “Development of Targeted New Agents for Children with Cancer.”, Cleveland, OH, November 8, 2013.
American Society for Bioethics and Humanities Annual Meeting, “Childhood cancer and chemotherapy shortages: Ethical challenges and tragic choices.”, Atlanta, GA, October 25, 2013.
Congressional Childhood Cancer Caucus 4th Annual Summit, Washington, DC, September 19, 2013.
American Society of Pediatric Hematology/Oncology Presidential Symposium, “Improving the Outcome for Children with Cancer: The Costs of Risk Aversion”, Miami, FL, April 25, 2013.
St Jude-Viva Forum in Pediatric Oncology, “Development of Targeted New Agents for Children with Cancer”, Singapore, March 8, 2013.
2013, National Cancer Institute Director’s Service Award for Outstanding and Dedicated Service to the Institute and the Clinical Trials and Translational Research Advisory Committee
2005, National Cancer Institute Special Recognition Award for Exceptional Service to the Clinical Trials Working Group of the National Cancer Advisory Board
2004, United States Army Medical Research and Material Command Certificate of Appreciation for support of the Congressionally Directed Medical Research Programs’ Neurofibromatosis Research Program
2004, United States Army Medical Research and Material Command Certificate of Appreciation for support of the Congressionally Directed Medical Research Programs’ Tuberous Sclerosis Complex Research Program
1992, Children's Cancer Foundation Research Scholar
1987, The Ritter Award, "Overall excellence in clinical and interpersonal skills"
1980, Phi Beta Kappa
1979, The Wesleyan Award, "Overall excellence in leadership and scholarship"
Pediatric Blood & Cancer
Pediatric Hematology and Oncology
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Journal of Clinical Oncology
Journal of Pediatric Hematology/Oncology
Journal of the National Cancer Institute
2007-present, CHOP Task Force on Industrial Relations Policy
CHOP Research Subject Recruitment Committee
CHOP Grants & Contracts Compliance Sub-committee
CHOP Research Compliance Oversight Committee
American Society for Clinical Pharmacology and Therapeutics
American College of Clinical Pharmacology
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
- 2007-present, Board of Directors
Society for Pediatric Research
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.